Information Provided By:
Fly News Breaks for August 7, 2019
Aug 7, 2019 | 07:02 EDT
RBC Capital analyst Brian Abrahams initiated Neurocrine with an Outperform rating and a price target of $118, saying the company's "high-growth, low-risk" profile should "continue to stand out." The analyst is positive on Neurocrine's strong near-term Ingrezza growth based on his market analysis, current trends, and physician feedback. Abrahams also believes the company has the potential for pipeline candidates to drive incremental longer-term revenue growth and sees that opportunity as "underappreciated" in the market.
News For NBIX From the Last 2 Days
There are no results for your query NBIX